Drugs / IVT Shigella-04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07205926 | Oct 2025 → Jan 2026 overdue | shigellosis | Inventprise Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVT Shigella-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07205926 ↗ |
| Known as | Shigella-04 | “First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults” NCT07205926 ↗ |
| Modality | Vaccine | “2-dose regimen of IM injection of 5 dose formulations of IVT Shigella-04 vaccine” NCT07205926 ↗ |
| Route | Intramuscular | “administered via intramuscular injection on Day 1 and 29” NCT07205926 ↗ |